Pulmotect Reports Positive Topline Results from Randomized, Placebo Controlled Phase-2 Trial of PUL-042 against COVID-19 Posted on September 21, 2021 by Brenton ScottPulmotect Appoints William J. Noss III as Chief Financial Officer
